Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of tinostamustine (EDO-S101) given
with or without radiation therapy in treating patients with newly diagnosed MGMT-unmethylated
glioblastoma. Tinostamustine may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth in patients with glioblastoma.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Mundipharma-EDO GmbH National Cancer Institute (NCI)